Unusual 11 Mid-Day Movers 9/29: (ITCI) (ADHD) (MRNS) Higher; (CATB) (AEGR) (DRNA) Lower

September 29, 2016 12:55 PM EDT

Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.

Intra-Cellular Therapies, Inc. (Nasdaq: ITCI) 63.1% LOWER; announced top-line results from the second Phase 3 clinical trial (Study ‘302) of ITI-007, an oral, first-in-class investigational medicine for the treatment of schizophrenia. In this trial, neither dose of ITI-007 separated from placebo on the primary endpoint, change from baseline on the Positive and Negative Syndrome Scale (PANSS) total score, in the pre-defined patient population.

Catabasis Pharmaceuticals, Inc. (Nasdaq: CATB) 59.0% HIGHER; Catabasis Pharma and Sarepta Therapeutics, Inc. (Nasdaq: SRPT) announced a joint research collaboration to explore a combination drug treatment approach for Duchenne muscular dystrophy (DMD). The two companies will contribute their respective expertise to study an exon skipping treatment developed by Sarepta, together with an oral NF-kB inhibition treatment developed by Catabasis in a mouse model of DMD.

Alcobra Ltd. (Nasdaq: ADHD) 54.6% LOWER; announced that it has received verbal notice from the Division of Psychiatry Products of the U.S. Food and Drug Administration (FDA) that a full clinical hold has been placed on its Investigational New Drug (IND) applications for MDX in ADHD and Fragile X Syndrome. The clinical hold affects Alcobra’s ongoing Phase III clinical study of MDX in adult patients with ADHD, known as the “MEASURE” study.

Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) 27.8% LOWER; announced top-line results from a Phase 2 exploratory open-label clinical trial evaluating ganaxolone, its CNS-selective GABAA modulator, in females with PCDH19 pediatric epilepsy. In the trial, ganaxolone reduced seizure frequency from baseline in the majority of patients enrolled in the study and was generally safe and well tolerated. PCDH19 pediatric epilepsy is a rare, serious epilepsy characterized by early-onset cluster seizures, cognitive and sensory impairment, and behavioral disturbances, with no approved treatments. In 2015, the U.S. Food and Drug Administration granted Orphan Drug Designation to ganaxolone for the treatment of PCDH19.

Actinium Pharmaceuticals, Inc. (NYSE: ATNM) 21.2% LOWER; announced the pricing of an underwritten public offering of 8,000,000 shares of its common stock at a price to the public of $1.25.

Aegerion Pharmaceuticals, Inc. (Nasdaq: AEGR) 19.7% HIGHER; announced that Japan’s Ministry of Health, Labor & Welfare (MHLW) has approved JUXTAPID for patients with homozygous familial hypercholesterolemia (HoFH).

Real Goods Solar (Nasdaq: RGSE) 16.1% LOWER; continuing to pullback following a 111 percent move higher earlier in the week.

Dicerna Pharmaceuticals (Nasdaq: DRNA) 13.7% HIGHER; continuing higher following a few days of gains this week.

REX Energy (Nasdaq: REXX) 12.3% HIGHER; Stifel upgraded REX Energy from Sell to Hold following yesterday's OPEC agreement.

Pacific Drilling (NYSE: PACD) 11.9% HIGHER; also gaining on rising crude prices today.

Mimecast Limited (Nasdaq: MIME) 11.6% HIGHER; announced the pricing of a registered secondary public offering of 4,000,000 ordinary shares at a price of $16.50 per share. The underwriters have a 30-day option to purchase up to an additional 600,000 ordinary shares at the public offering price, less underwriting discounts and commissions. All of the shares are being sold by Mimecast’s shareholders. Mimecast will not receive any proceeds from the sale of these shares.

To get this report daily visit http://www.streetinsider.com/entities/Unusual+11+Mid-Day+Movers.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Special Reports

Related Entities

Stifel, The Children's Investment Fund (TCI), Crude Oil, Unusual 11 Mid-Day Movers, OPEC

Add Your Comment